Table 1.

gB-specific mAb immunogenetics, binding strength, and avidity to full length gB and gB ectodomain

Monoclonal Antibody	Heavy Chain ^a	Light Chain ^a	CDRH3 Length ^a	Neutralization IC50 (μg/mL) ^a	Epitope Specificity	Full length gB binding EC₅₀ (μg/mL)^b	gB ectodomain binding EC₅₀ (μg/mL) ^b	gB ectodomain apparent avdity KD (nM) ^c
1-155	IGHV1-69*01	IGLV2-11*01	14	0	Cytodomain	0.002	6.903	6.2
1-189	IGHV1-69*01	IGKV4-1*01	11	0	Conformational	0.007	2.562	702
1-190	IGHV1-69*01	IGKV4-1*01	11	0	Conformational	0.019	3.716	1.88
1-191	IGHV1-69*01	IGKV4-1*01	11	0	Conformational	0.009	6.163	10.8
1-192	IGHV1-69*06	IGKV4-1*01	11	0	Conformational	0.010	> 100	116
1-193	IGHV1-18*01	IGKV2-30*01	22	1	AD2 Site 2	0.003	0.004	0.0003
1-223	IGHV1-69*03	IGLV2-23*01	22	8.3	AD2 Site 1/Site 2	0.009	0.013	0.301
1-224	IGHV1-69*03	IGKV3-20*01	22	6.4	Conformational	0.006	0.011	0.116
1-228	IGHV3-13*01	IGKV1-33*01	10	0	Domain II	0.001	8.014	N.D.
1-235	IGHV4-31*03	IGKV4-1*01	11	0	AD2 Site 1/Site 2	0.001	0.002	0.019
1-237	IGHV1-69*01	IGKV4-1*01	12	0	Cytodomain	0.003	2.656	5.27

2-16	IGHV1-69*01	IGKV3-15*01	15	11	Domain II	0.002	0.004	0.0004
2-32	IGHV4-59*01	IGKV4-1*01	12	0	Conformational	0.003	0.006	N.D.
2-43	IGHV6-1*01	IGKV4-1*01	14	15	Conformational	0.003	0.004	0.0034
2-45	IGHV4-34*02	IGKV3-15*01	24	9.8	AD2 Site 2	0.003	0.006	0.0004
2-48	IGHV1-2*02	IGKV3-20*01	14	14.6	Domain II	0.003	0.006	0.113
2-59	IGHV4-34*02	IGLV1-47*01	18	2.3	Domain II	0.006	0.010	0.0016
2-65	IGHV1-2*02	IGKV3-20*01	14	6.4	Domain II	0.007	0.018	0.081

3-18	IGHV3-21*01	IGKV1D-8*01	26	0	Cytodomain	16.370	> 100	22.5
3-38	IGHV1-18*01	IGKV4-1*01	14	0	AD2 Site 2	0.006	0.008	0.0003
3-54	IGHV1-46*01	IGKV1-5*03	22	1	Domain II	0.006	0.011	0.474
3-58	IGHV3-30*03	IGLV3-10*01	34	0	Domain II	5.733	20.560	1.82
3-65	IGHV3-33*01	IGKV4-1*01	16	0	Domain II	0.003	0.003	0.036
3-74	IGHV3-30-3*01	IGLV3-25*03	28	0	Domain II	0.601	0.723	1.52

^a.

Heavy chain and light chain genes, as well as CDRH3 length listed as described in (Xia et al 2017).

^b.

Neutralization previously defined as an IC₅₀ < 1 (μg/mL) by (Xia et al 2017), ”> xx” no neutralization at the highest dilution at which the mAb was tested

^c.

binding to full length gB and post fusion gB ectodomain EC₅₀ (μg/mL) measured by ELISA.

^d.

binding kinetics to post fusion gB ectodomain measured by SPR